Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$25.3K Sell
112
-8
-7% -$1.7K ﹤0.01% 1908
2026
Q2
$25.9K Buy
120
+9
+8% +$1.72K ﹤0.01% 1884
2026
Q1
$20.3K Sell
111
-9
-8% -$1.66K ﹤0.01% 1705
2025
Q4
$21.1K Hold
120
– – ﹤0.01% 1734
2025
Q3
$16.8K Sell
120
-20
-14% -$2.7K ﹤0.01% 1667
2025
Q2
$17.6K Sell
140
-452
-76% -$56.3K ﹤0.01% 1548
2025
Q1
$81K Buy
592
+99
+20% +$14.2K 0.01% 937
2024
Q4
$75.4K Sell
493
-230
-32% -$38.8K 0.01% 967
2024
Q3
$140K Buy
+723
New +$151K 0.01% 751

Other funds holding BIIB

BFC Planning's BIIB Position: Q3 2026 in Review

BFC Planning reduced its Biogen (BIIB) stake by 6.7% in Q3 2026, selling an estimated $1.7K and leaving 112 shares worth $25.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1908.

BFC Planning first reported a position in BIIB in Q3 2024 and has held it in 9 quarters since. The position peaked at $140K in Q3 2024. 913 funds tracked by Wall St. Rank hold BIIB as of Q3 2026.

  • BFC Planning held 112 shares of Biogen worth $25.3K as of Q3 2026.
  • BFC Planning sold 8 Biogen shares in Q3 2026, an estimated $1.7K.
  • Biogen made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1908 holding.
  • BFC Planning first reported a position in Biogen in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Biogen position peaked at $140K in Q3 2024.
  • 913 funds tracked by Wall St. Rank held Biogen as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.